Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis

被引：2
|
作者：
Cheng, Hai-peng [1 ,2 ]
Jiang, Shi-he [1 ,2 ]
Cai, Jin [1 ,2 ]
Luo, Zi-qiang [3 ,4 ]
Li, Xiao-hong [1 ,2 ]
Feng, Dan-dan [3 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha, Hunan, Peoples R China
[2] Hunan Clin Med Res Ctr Canc Pathogen Genes Testing, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Xiangya Sch Med, Dept Physiol, Changsha, Hunan, Peoples R China
[4] Cent South Univ, Hunan Key Lab Organ Fibrosis, Changsha, Hunan, Peoples R China
来源：
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2024年 / 12卷
关键词：
histone deacetylase; idiopathic pulmonary fibrosis; histone acetylation; fibroblasts; HDAC inhibitors; EPITHELIAL-MESENCHYMAL TRANSITION; DNA METHYLATION; VALPROIC ACID; GENE-EXPRESSION; KAPPA-B; INHIBITOR; CELLS; DIFFERENTIATION; ACETYLATION; CLONING;
D O I：
10.3389/fcell.2024.1426508
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown origin and the most common interstitial lung disease. However, therapeutic options for IPF are limited, and novel therapies are urgently needed. Histone deacetylases (HDACs) are enzymes that participate in balancing histone acetylation activity for chromatin remodeling and gene transcription regulation. Increasing evidence suggests that the HDAC family is linked to the development and progression of chronic fibrotic diseases, including IPF. This review aims to summarize available information on HDACs and related inhibitors and their potential applications in treating IPF. In the future, HDACs may serve as novel targets, which can aid in understanding the etiology of PF, and selective inhibition of single HDACs or disruption of HDAC genes may serve as a strategy for treating PF.
引用
收藏
页数：12
相关论文
共 50 条
  • [21] LOX/LOXL in pulmonary fibrosis: potential therapeutic targets
    Chen, Lijun
    Li, Shifeng
    Li, Wande
    JOURNAL OF DRUG TARGETING, 2019, 27 (07) : 790 - 796
  • [22] Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer
    Xiang, Xue-Song
    Li, Peng-Cheng
    Wang, Wen-Quan
    Liu, Liang
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (01):
  • [23] Histone deacetylases as therapeutic targets - From cancer to cardiac disease
    Abend, Alon
    Kehat, Izhak
    PHARMACOLOGY & THERAPEUTICS, 2015, 147 : 55 - 62
  • [24] Aberrant Expression And Activity Of Histone Deacetylases (hdacs) In Lungs Of Patients With Sporadic Idiopathic Pulmonary Fibrosis (ipf)
    Korfei, M.
    Skwarna, S.
    Klymenko, O.
    Von der Beck, D.
    Mehta, A.
    Oeztuerk, N.
    Klepetko, W.
    Fink, L.
    Barreto, G.
    Seeger, W.
    Kramer, O. H.
    Guenther, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [25] Pathogenetic pathways and novel pharmaco therapeutic targets in idiopathic pulmonary fibrosis
    Antomou, Katerma M.
    Pataka, Athanasia
    Bouros, Demosthenes
    Slafakas, Nikolaos M.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (05) : 453 - 461
  • [26] Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis
    Rubio, Karla
    Singh, Indrabahadur
    Dobersch, Stephanie
    Sarvari, Pouya
    Guenther, Stefan
    Cordero, Julio
    Mehta, Aditi
    Wujak, Lukasz
    Cabrera-Fuentes, Hector
    Chao, Cho-Ming
    Braubach, Peter
    Bellusci, Saverio
    Seeger, Werner
    Guenther, Andreas
    Preissner, Klaus T.
    Wygrecka, Malgorzata
    Savai, Rajkumar
    Papy-Garcia, Dulce
    Dobreva, Gergana
    Heikenwalder, Mathias
    Savai-Pullamsetti, Soni
    Braun, Thomas
    Barreto, Guillermo
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [27] Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis
    Karla Rubio
    Indrabahadur Singh
    Stephanie Dobersch
    Pouya Sarvari
    Stefan Günther
    Julio Cordero
    Aditi Mehta
    Lukasz Wujak
    Hector Cabrera-Fuentes
    Cho-Ming Chao
    Peter Braubach
    Saverio Bellusci
    Werner Seeger
    Andreas Günther
    Klaus T. Preissner
    Malgorzata Wygrecka
    Rajkumar Savai
    Dulce Papy-Garcia
    Gergana Dobreva
    Mathias Heikenwalder
    Soni Savai-Pullamsetti
    Thomas Braun
    Guillermo Barreto
    Nature Communications, 10
  • [28] Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
    Wang, Guan
    He, Jing
    Zhao, Jianyun
    Yun, Wenting
    Xie, Chengzhi
    Taub, Jeffrey W.
    Azmi, Asfar
    Mohammad, Ramzi M.
    Dong, Yan
    Kong, Wei
    Guo, Yingjie
    Ge, Yubin
    PLOS ONE, 2012, 7 (12):
  • [29] Genetic insights into idiopathic pulmonary fibrosis: a multi-omics approach to identify potential therapeutic targets
    Wen, Zhuofeng
    Liang, Weixuan
    Yang, Ziyang
    Liu, Junjie
    Yang, Jing
    Xu, Runge
    Lin, Keye
    Pan, Jia
    Chen, Zisheng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [30] Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension
    He, Wenjun
    Su, Xi
    Chen, Lingdan
    Liu, Chunli
    Lu, Wenju
    Wang, Tao
    Wang, Jian
    PHYSIOLOGICAL REPORTS, 2022, 10 (01):
12345